COMP <GO>
BVS vs MRK // GROSS PROFIT MARGIN
Bioventus Inc. (Class A) (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: BVS 2
— MRK 10
▲ GROSS PROFIT MARGIN LEADER: MRK
LAST: $13.33 (-10.39%) • MKT CAP: $1.25B
gross-margins
68.30%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BVS VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BVS | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 68.30% | 74.80% | -6.50 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.40% | 20.70% | -10.30 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 26.3x | 15.3x | +11.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 5.77% | 3.42% | +2.35 | BVS | /fcf-yield <GO> |
| Operating Margin | 9.50% | 34.30% | -24.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 4.00% | 28.10% | -24.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 1.30% | -2.20 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.25 | 5.19 | -2.94 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.4 | 51.7 | +5.70 | BVS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 51.2x | 18.4x | +32.80 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.25B | $361.02B | -$359.77B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BVS REV | MRK REV | BVS GROSS % | MRK GROSS % | BVS FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $568.1M | $65.01B | 68.3% | 74.8% | $72.1M | $12.36B |
| FY 2024 | $573.3M | $64.17B | 67.7% | 76.3% | $37.8M | $18.10B |
| FY 2023 | $512.3M | $60.12B | — | — | $15.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BVS // BETA —
MRK // BETA 0.92